Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Neuroendocrine TumorsCarcinoid Tumor
Interventions
DRUG

Quarfloxin

IV Quarfloxin 240 mg/m2 daily x5 days every 21 days

Trial Locations (13)

34471

Ocala

75246

Texas Oncology, Dallas

75702

Tyler Cancer Center, Tyler

78229

UT Health Science Center, San Antonio

80218

Rocky Mountain Cancer Centers, Denver

98101

Virginia Mason Medical Center, Seattle

98684

Northwest Cancer Specialists, Vancouver

Unknown

Birmingham Hematology and Oncology, Birmingham

Front Range Cancer Specialists, Fort Collins

Southern New Mexico Cancer Center, Las Cruces

Texas Oncology, Amarillo

El Paso Cancer Treatment Center, El Paso

Cancer Care Centers of South Texas, Kerrville

Sponsors
All Listed Sponsors
lead

Cylene Pharmaceuticals

INDUSTRY